At the recent presentation, I thought the most interesting bit of info was Pucci insisting that ARQL could go from expanded Phase I studies with 092 and 087 right into registration trials.
I still hold out hope for Tivantinib in 2nd line HCC. If successful there, then there is the possibility of going to first-line in combo with Nexavar.
Market Data 
Markets 
AI
